The stock was the top percentage gainer on the Nifty Pharma index, which traded 0.3% higher compared to a 0.8% loss in the ...

Glenmark Pharmaceuticals' shares surged 10% to an all-time high of ₹2,094 following the announcement of an exclusive ...

By Kashish Tandon (Reuters) -Shares of India's Glenmark Pharmaceuticals jumped 10% to a record high on Friday, a day after ...

AbbVie Inc. defeated class action claims it misled investors about the role kickbacks played in the success of its arthritis ...

Tremfya snagged Dupixent’s place as the pharma brand with the most TV impressions in June, according to data released by iSpot.tv on Friday morning. The Johnson & Johnson brand garnered a 4.3% share ...

The antibody, ISB 2001, is currently in Phase 1 clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM) ...

The investment landscape is shifting as companies show resilience and innovation, prompting investors to reassess portfolios. AbbVie, Boeing, Oracle, and Joby Aviation mentioned as potential ...

Glenmark Pharmaceuticals Ltd's shares soared over 14% after announcing a deal with AbbVie worth up to USD 2 billion. The ...

The healthcare industry is a behemoth, with annual expenditures totaling $4.9 trillion in the United States alone. It's a ...

AbbVie’s projected 2025 earnings just got trimmed by Cantor Fitzgerald, slicing estimates from $12.31 per share to $11.84.

A Financial District-based drug discovery company inked a $1 billion licensing agreement with pharmaceutical giant AbbVie to develop its signature cancer drug. IGI Therapeutics SA, a subsidiary of the ...

Glenmark Pharmaceuticals Ltd.’s licensing pact with AbbVie Inc. for its blood cancer drug is boosting optimism over Indian ...